Cargando…

Magnitude of and Characteristics Associated With the Treatment of Calcium Channel Blocker–Induced Lower-Extremity Edema With Loop Diuretics

IMPORTANCE: Calcium channel blockers, specifically dihydropyridine calcium channel blockers (DH CCBs, eg, amlodipine), may cause lower-extremity edema. Anecdotal reports suggest this may result in a prescribing cascade, where DH CCB–induced edema is treated with loop diuretics. OBJECTIVE: To assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Vouri, Scott Martin, Jiang, Xinyi, Manini, Todd M., Solberg, Laurence M., Pepine, Carl, Malone, Daniel C., Winterstein, Almut G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991233/
https://www.ncbi.nlm.nih.gov/pubmed/31880802
http://dx.doi.org/10.1001/jamanetworkopen.2019.18425
_version_ 1783492615960788992
author Vouri, Scott Martin
Jiang, Xinyi
Manini, Todd M.
Solberg, Laurence M.
Pepine, Carl
Malone, Daniel C.
Winterstein, Almut G.
author_facet Vouri, Scott Martin
Jiang, Xinyi
Manini, Todd M.
Solberg, Laurence M.
Pepine, Carl
Malone, Daniel C.
Winterstein, Almut G.
author_sort Vouri, Scott Martin
collection PubMed
description IMPORTANCE: Calcium channel blockers, specifically dihydropyridine calcium channel blockers (DH CCBs, eg, amlodipine), may cause lower-extremity edema. Anecdotal reports suggest this may result in a prescribing cascade, where DH CCB–induced edema is treated with loop diuretics. OBJECTIVE: To assess the magnitude and characteristics of the DH CCB prescribing cascade. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used a prescription sequence symmetry analysis to assess loop diuretic initiation before and after the initiation of DH CCBs among patients aged 20 years or older without heart failure. Data from a private insurance claims database from 2005 to 2017 was analyzed. Use of loop diuretics associated with initiation of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and other commonly used medications was used as negative controls. Data were analyzed from March 2019 through October 2019. EXPOSURES: Initiation of DH CCB or negative control medications. MAIN OUTCOMES AND MEASURES: The temporality of loop diuretic initiation relative to DH CCB or negative control initiation. Secular trend-adjusted sequence ratios (aSRs) with 95% CIs were calculated using data from 360 days before and after initiation of DH CCBs. RESULTS: Among 1 206 093 DH CCB initiators, 55 818 patients (4.6%) (33 100 [59.3%] aged <65 years; 32 916 [59.0%] women) had a new loop diuretic prescription 360 days before or after DH CCB initiation, resulting in an aSR of 1.87 (95% CI, 1.84-1.90). An estimated 1.44% of DH CCB initiators experienced the prescribing cascade. The aSR was disproportionately higher among DH CCB initiators who were prescribed high doses (aSR, 2.20; 95% CI, 2.13-2.27), initiated amlodipine (aSR, 1.89; 95% CI, 1.86-1.93), were men (aSR, 1.96; 95% CI, 1.91-2.01), and used fewer antihypertensive classes (aSR, 2.55; 95% CI, 2.47-2.64). The evaluation of ACE inhibitors or ARBs as negative controls suggested hypertension progression may have tempered the incidence of the prescribing cascade (aSR for ACE inhibitors and ARBs, 1.27; 95% CI, 1.24-1.29). CONCLUSIONS AND RELEVANCE: This study found an excessive use of loop diuretics following initiation of DH CCBs that cannot be completely explained by secular trends or hypertension progression. The prescribing cascade was more pronounced among those initially prescribed a high dose of DH CCBs.
format Online
Article
Text
id pubmed-6991233
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-69912332020-02-11 Magnitude of and Characteristics Associated With the Treatment of Calcium Channel Blocker–Induced Lower-Extremity Edema With Loop Diuretics Vouri, Scott Martin Jiang, Xinyi Manini, Todd M. Solberg, Laurence M. Pepine, Carl Malone, Daniel C. Winterstein, Almut G. JAMA Netw Open Original Investigation IMPORTANCE: Calcium channel blockers, specifically dihydropyridine calcium channel blockers (DH CCBs, eg, amlodipine), may cause lower-extremity edema. Anecdotal reports suggest this may result in a prescribing cascade, where DH CCB–induced edema is treated with loop diuretics. OBJECTIVE: To assess the magnitude and characteristics of the DH CCB prescribing cascade. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used a prescription sequence symmetry analysis to assess loop diuretic initiation before and after the initiation of DH CCBs among patients aged 20 years or older without heart failure. Data from a private insurance claims database from 2005 to 2017 was analyzed. Use of loop diuretics associated with initiation of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and other commonly used medications was used as negative controls. Data were analyzed from March 2019 through October 2019. EXPOSURES: Initiation of DH CCB or negative control medications. MAIN OUTCOMES AND MEASURES: The temporality of loop diuretic initiation relative to DH CCB or negative control initiation. Secular trend-adjusted sequence ratios (aSRs) with 95% CIs were calculated using data from 360 days before and after initiation of DH CCBs. RESULTS: Among 1 206 093 DH CCB initiators, 55 818 patients (4.6%) (33 100 [59.3%] aged <65 years; 32 916 [59.0%] women) had a new loop diuretic prescription 360 days before or after DH CCB initiation, resulting in an aSR of 1.87 (95% CI, 1.84-1.90). An estimated 1.44% of DH CCB initiators experienced the prescribing cascade. The aSR was disproportionately higher among DH CCB initiators who were prescribed high doses (aSR, 2.20; 95% CI, 2.13-2.27), initiated amlodipine (aSR, 1.89; 95% CI, 1.86-1.93), were men (aSR, 1.96; 95% CI, 1.91-2.01), and used fewer antihypertensive classes (aSR, 2.55; 95% CI, 2.47-2.64). The evaluation of ACE inhibitors or ARBs as negative controls suggested hypertension progression may have tempered the incidence of the prescribing cascade (aSR for ACE inhibitors and ARBs, 1.27; 95% CI, 1.24-1.29). CONCLUSIONS AND RELEVANCE: This study found an excessive use of loop diuretics following initiation of DH CCBs that cannot be completely explained by secular trends or hypertension progression. The prescribing cascade was more pronounced among those initially prescribed a high dose of DH CCBs. American Medical Association 2019-12-27 /pmc/articles/PMC6991233/ /pubmed/31880802 http://dx.doi.org/10.1001/jamanetworkopen.2019.18425 Text en Copyright 2019 Vouri SM et al. JAMA Network Open. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Vouri, Scott Martin
Jiang, Xinyi
Manini, Todd M.
Solberg, Laurence M.
Pepine, Carl
Malone, Daniel C.
Winterstein, Almut G.
Magnitude of and Characteristics Associated With the Treatment of Calcium Channel Blocker–Induced Lower-Extremity Edema With Loop Diuretics
title Magnitude of and Characteristics Associated With the Treatment of Calcium Channel Blocker–Induced Lower-Extremity Edema With Loop Diuretics
title_full Magnitude of and Characteristics Associated With the Treatment of Calcium Channel Blocker–Induced Lower-Extremity Edema With Loop Diuretics
title_fullStr Magnitude of and Characteristics Associated With the Treatment of Calcium Channel Blocker–Induced Lower-Extremity Edema With Loop Diuretics
title_full_unstemmed Magnitude of and Characteristics Associated With the Treatment of Calcium Channel Blocker–Induced Lower-Extremity Edema With Loop Diuretics
title_short Magnitude of and Characteristics Associated With the Treatment of Calcium Channel Blocker–Induced Lower-Extremity Edema With Loop Diuretics
title_sort magnitude of and characteristics associated with the treatment of calcium channel blocker–induced lower-extremity edema with loop diuretics
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991233/
https://www.ncbi.nlm.nih.gov/pubmed/31880802
http://dx.doi.org/10.1001/jamanetworkopen.2019.18425
work_keys_str_mv AT vouriscottmartin magnitudeofandcharacteristicsassociatedwiththetreatmentofcalciumchannelblockerinducedlowerextremityedemawithloopdiuretics
AT jiangxinyi magnitudeofandcharacteristicsassociatedwiththetreatmentofcalciumchannelblockerinducedlowerextremityedemawithloopdiuretics
AT maninitoddm magnitudeofandcharacteristicsassociatedwiththetreatmentofcalciumchannelblockerinducedlowerextremityedemawithloopdiuretics
AT solberglaurencem magnitudeofandcharacteristicsassociatedwiththetreatmentofcalciumchannelblockerinducedlowerextremityedemawithloopdiuretics
AT pepinecarl magnitudeofandcharacteristicsassociatedwiththetreatmentofcalciumchannelblockerinducedlowerextremityedemawithloopdiuretics
AT malonedanielc magnitudeofandcharacteristicsassociatedwiththetreatmentofcalciumchannelblockerinducedlowerextremityedemawithloopdiuretics
AT wintersteinalmutg magnitudeofandcharacteristicsassociatedwiththetreatmentofcalciumchannelblockerinducedlowerextremityedemawithloopdiuretics